Generic Wellbutrin ( Bupropion )

Buy Generic Wellbutrin (Bupropion) without prescription in Canada

In our Canadian pharmacy, you can buy Wellbutrin (Bupropion) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Wellbutrin (bupropion hydrochloride) is an atypical antidepressant belonging to the aminoketone class. It acts primarily as a norepinephrine‑dopamine reuptake inhibitor (NDRI), increasing the synaptic availability of both norepinephrine and dopamine in the brain, without clinically significant effects on serotonin. This unique mechanism helps relieve the symptoms of major depression—particularly fatigue, poor concentration, and anhedonia—while offering a favourable profile with regard to sexual function and body weight. Bupropion is also effective for the prevention of seasonal affective disorder (SAD) and, in its sustained‑release formulation, as an aid to smoking cessation.

Usual adult dose: For major depressive disorder, the recommended starting dose is 150 mg taken once daily in the morning. After 4 days, the dose may be increased to the target dose of 300 mg once daily in the morning. For prevention of seasonal affective disorder, treatment should be initiated in the autumn before the onset of depressive symptoms; the starting dose is 150 mg once daily, increased after 7 days to 300 mg once daily. The maximum recommended dose is 300 mg once daily for both indications. Doses above 300 mg per day have not been assessed in SAD trials and are associated with an increased risk of seizures.

Dosage form: Extended‑release (XL) tablets: 150 mg and 300 mg.

Onset of action: Some improvement in energy, sleep, or appetite may be noticed within the first 1 to 2 weeks of treatment. However, the full antidepressant effect typically requires 4 weeks or longer of continuous therapy. For smoking cessation, bupropion should be started at least 1 week before the target quit date.

Duration of action: The elimination half‑life of bupropion is approximately 21 hours (range 12 to 30 hours), and its active metabolites have half‑lives of 20 to 37 hours. This supports once‑daily dosing with the extended‑release formulation. Steady‑state plasma concentrations are reached within 8 days.

Alcohol recommendation: Alcohol consumption should be strictly avoided or limited to a minimum during treatment with Wellbutrin. Bupropion lowers the seizure threshold, and abrupt discontinuation of alcohol in heavy drinkers can further increase the risk of seizures. Alcohol may also worsen neuropsychiatric side effects such as agitation, anxiety, and insomnia.

Most common side effects: Insomnia (11‑40%), dry mouth (up to 28%), headache (up to 34%), nausea (up to 23%), agitation/anxiety (2‑32%), dizziness, constipation, excessive sweating, tremor, and tachycardia. Weight loss rather than weight gain is typical with bupropion. These side effects are often most pronounced during the first weeks of therapy and tend to diminish with continued use.

Would you like to try Wellbutrin (Bupropion) without a prescription?

General Information about Wellbutrin (Bupropion)

• INN (International Nonproprietary Name): Bupropion (as bupropion hydrochloride).
• Brand names available in Canada: Wellbutrin® XL (Bausch Health, Canada Inc.), TEVA‑Bupropion XL (Teva Canada Limited), TARO‑Bupropion XL (Sun Pharma Canada Inc.), MYLAN‑Bupropion XL (Mylan Pharmaceuticals ULC — cancelled post‑market), ODAN‑Bupropion SR (Odan Laboratories Ltd.), PMS‑Bupropion SR (Pharmascience Inc.), APO‑Bupropion SR (Apotex Inc.), and generic formulations from multiple Canadian manufacturers. Zyban® (bupropion SR) was previously marketed as a smoking cessation aid. Additional generic manufacturers include JAMP Pharma Corporation, Sanis Health Inc., and Marcan Pharmaceuticals Inc.
• ATC code: N06AX12 (other antidepressants).
• Dosage forms and strengths: Extended‑release (XL) tablets: 150 mg and 300 mg. Sustained‑release (SR) tablets: 100 mg and 150 mg. An immediate‑release formulation is not commonly available in Canada. The XL formulation is the preferred option for once‑daily dosing, providing stable blood levels and lower peak concentrations, which may reduce seizure risk.
• Manufacturers in Canada: Bausch Health, Canada Inc. (Wellbutrin XL, DINs 02275090 and 02275104), Teva Canada Limited (TEVA‑Bupropion XL, DINs 02439654 and 02439662), Sun Pharma Canada Inc. (TARO‑Bupropion XL, DIN 02475812), Odan Laboratories Ltd. (ODAN‑Bupropion SR), Pharmascience Inc. (PMS‑Bupropion SR), Apotex Inc., JAMP Pharma Corporation, Sanis Health Inc., Marcan Pharmaceuticals Inc., and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. Marketed. The original Wellbutrin XL received its Notice of Compliance on November 22, 2005, and was first marketed on February 2, 2006. Multiple generic formulations are currently marketed and available by prescription.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. Wellbutrin is not available over the counter and requires a valid prescription from a licensed Canadian healthcare professional.

Mechanism of Action and Pharmacology

Bupropion is an aminoketone antidepressant structurally related to amphetamine but with a distinct pharmacological profile. Its primary mechanism of action is the inhibition of the presynaptic reuptake of norepinephrine (NE) and dopamine (DA) by blocking the norepinephrine transporter (NET) and the dopamine transporter (DAT), respectively. Unlike selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs), bupropion has no clinically significant effect on serotonin reuptake and does not bind to serotonergic, adrenergic, muscarinic cholinergic, or histaminergic receptors. This unique NDRI profile is thought to account for its efficacy in depression with prominent fatigue, poor concentration, and anhedonia, and for its favourable side‑effect profile regarding sexual dysfunction and weight gain.

Bupropion is also a non‑competitive antagonist of α3β4 nicotinic acetylcholine receptors, and its active metabolite hydroxybupropion is a more potent non‑competitive antagonist of α4β2 nicotinic receptors. This nicotinic receptor antagonism is believed to play a role in its efficacy for smoking cessation by attenuating the rewarding effects of nicotine.

Following oral administration, bupropion is rapidly and completely absorbed, with peak plasma concentrations reached within approximately 5 hours for the extended‑release formulation. Bupropion undergoes extensive first‑pass hepatic metabolism, primarily via cytochrome P450 2B6 (CYP2B6), to form three active metabolites: hydroxybupropion, threohydrobupropion, and erythrohydrobupropion. These metabolites have half‑lives of 20 to 37 hours and exhibit approximately 20% to 50% of the pharmacological potency of the parent compound. The elimination half‑life of bupropion itself is approximately 21 hours (range 12–30 hours), which is prolonged in patients with hepatic cirrhosis and moderate‑to‑severe renal impairment. Bupropion is a strong inhibitor of CYP2D6 and may increase plasma concentrations of drugs metabolised by this isoenzyme. The drug and its metabolites are excreted primarily in the urine (87%) and, to a lesser extent, in the faeces (10%). Steady‑state plasma concentrations are reached within 8 days of regular once‑daily dosing. Bupropion is not dialyzable to any significant extent.

Indications

• Major Depressive Disorder (MDD): Wellbutrin XL is indicated for the treatment of major depressive disorder in adults. It may be particularly useful for patients whose depression is associated with prominent fatigue, poor concentration, anhedonia, hypersomnia, or weight gain.
• Seasonal Affective Disorder (SAD): Wellbutrin XL is indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder. Treatment should be initiated in the autumn, prior to the onset of depressive symptoms, and continued through the winter season, with tapering and discontinuation in early spring.
• Smoking Cessation (off‑label for XL formulation): Bupropion SR (Zyban) is approved in Canada as an aid to smoking cessation. Bupropion XL is also used off‑label for this purpose.
• Off‑label uses: Bupropion is prescribed off‑label for attention‑deficit/hyperactivity disorder (ADHD), antidepressant‑induced sexual dysfunction, bipolar depression (in combination with a mood stabiliser), and obesity.
• Wellbutrin is not approved for use in children and adolescents under 18 years of age.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Bupropion should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the foetus. Systematic reviews and manufacturer data have found no increased risk of major malformations overall compared with the general population, though some individual studies have suggested a possible association with cardiac abnormalities. The decision to continue or discontinue bupropion during pregnancy should be made in consultation with a healthcare provider. Women of childbearing potential should use effective contraception.
• Breastfeeding: Bupropion is excreted in human breast milk in low amounts (approximately 2% of the maternal weight‑adjusted dose). It is generally considered acceptable during breastfeeding, but rare case reports of seizure‑like episodes in breastfed infants exist. Nursing infants should be monitored for sedation, changes in feeding patterns, and seizure‑like activity.
• Paediatrics (< 18 years): Safety and efficacy have not been established in children and adolescents. Wellbutrin is not approved for use in this population. Antidepressants increase the risk of suicidal thinking and behaviour in children, adolescents, and young adults.
• Elderly: No routine dose adjustment is required based on age alone. However, elderly patients may be at greater risk of drug accumulation during chronic dosing due to age‑related decline in renal and hepatic function. Lower starting doses and careful monitoring are recommended.
• Hepatic impairment: In patients with moderate to severe hepatic impairment (Child‑Pugh B or C), the maximum recommended dose is 150 mg every other day. In patients with mild hepatic impairment (Child‑Pugh A), a reduction in dose and/or frequency of dosing should be considered. Bupropion is extensively metabolised by the liver, and clearance is reduced in hepatic impairment.
• Renal impairment: In patients with moderate renal impairment (creatinine clearance 15–60 mL/min), a maximum daily dose of 150 mg is recommended. In patients with end‑stage renal disease, bupropion should be used with extreme caution, and alternative agents are preferred. The active metabolites of bupropion accumulate in renal impairment.
• Seizure disorders: Bupropion lowers the seizure threshold and is contraindicated in patients with a current or prior seizure disorder. The seizure risk is dose‑dependent, with an incidence of approximately 0.1% (1/1,000) at doses up to 300 mg/day of the SR formulation and 0.4% (4/1,000) at 400 mg/day. The risk increases almost tenfold between 450 mg and 600 mg/day. Additional risk factors include: history of head trauma, arteriovenous malformation, CNS tumour or infection, severe stroke, eating disorders (anorexia nervosa or bulimia), abrupt discontinuation of alcohol or sedatives, use of other medications that lower the seizure threshold, and metabolic disorders such as hypoglycaemia and hyponatraemia.
• Eating disorders: Bupropion is contraindicated in patients with a current or prior diagnosis of bulimia nervosa or anorexia nervosa due to the increased risk of seizures in this population.
• Bipolar disorder: Screen patients for bipolar disorder and risk factors for bipolar disorder prior to initiating treatment. Antidepressants, including bupropion, can precipitate a manic, mixed, or hypomanic episode. While early studies suggested lower switch rates with bupropion, current evidence indicates that switch rates are comparable to those of other antidepressants. Wellbutrin is not approved for the treatment of bipolar depression.
• Cardiovascular disease: Bupropion can increase blood pressure. Blood pressure should be assessed before initiating therapy and monitored periodically during treatment. Bupropion should be used with caution in patients with pre‑existing hypertension, recent myocardial infarction, unstable cardiac disease, or congestive heart failure.
• Angle‑closure glaucoma: The pupillary dilation that occurs with many antidepressants, including bupropion, may trigger an acute angle‑closure attack in patients with anatomically narrow angles who do not have a patent iridectomy. Patients at risk should have an ophthalmologic evaluation before starting therapy.
• Suicidality: Antidepressants, including bupropion, carry a boxed warning for an increased risk of suicidal thinking and behaviour in children, adolescents, and young adults aged 24 years and under during the first few months of treatment. All patients should be closely monitored for clinical worsening, suicidality, or unusual changes in behaviour, particularly during the initial few months of therapy and after dosage changes.
• Hypersensitivity reactions: Anaphylactoid and anaphylactic reactions, including pruritus, urticaria, angioedema, and dyspnoea, have occurred with bupropion. Rare post‑marketing reports include erythema multiforme, Stevens‑Johnson syndrome, and anaphylactic shock. Serum sickness‑like reactions (arthralgia, myalgia, fever with rash) suggestive of delayed hypersensitivity have also been reported. Bupropion should be discontinued immediately at the first sign of an allergic reaction.
• Allergy: Do not take Wellbutrin if you have a known hypersensitivity to bupropion hydrochloride or any excipient in the formulation.

Driving and alcohol

Wellbutrin may cause dizziness, drowsiness, blurred vision, and impaired cognitive and motor skills, particularly during the first few weeks of therapy and after dose increases. Patients should not drive, operate heavy machinery, or engage in potentially hazardous activities until they have determined how the medication affects them. Alcohol consumption should be strictly avoided or limited to a minimum during treatment with Wellbutrin. Bupropion lowers the seizure threshold, and excessive use of alcohol or abrupt discontinuation of alcohol in heavy drinkers can substantially increase the risk of seizures. Alcohol may also potentiate the neuropsychiatric side effects of bupropion, including agitation, anxiety, and insomnia.

Dosage Instructions

• Major Depressive Disorder (Adults): The recommended starting dose is 150 mg taken orally once daily in the morning. After 4 days of dosing, the dose may be increased to the target dose of 300 mg once daily in the morning. It is generally agreed that acute episodes of depression require several months or longer of sustained pharmacological therapy beyond the initial response. Periodically reassess the need for maintenance treatment and the appropriate dose.
• Seasonal Affective Disorder (Adults): The recommended starting dose is 150 mg once daily. After 7 days of dosing, the dose may be increased to the target dose of 300 mg once daily in the morning. Doses above 300 mg were not assessed in the SAD trials. Initiate treatment in the autumn, prior to the onset of depressive symptoms. Continue treatment through the winter season. Taper and discontinue in early spring: for patients on 300 mg per day, decrease the dose to 150 mg once daily before discontinuing.
• Hepatic impairment: In patients with moderate to severe hepatic impairment (Child‑Pugh B or C), the maximum dose is 150 mg every other day. In mild hepatic impairment, consider reducing the dose and/or frequency of dosing.
• Renal impairment: In patients with moderate renal impairment (CrCl 15–60 mL/min), consider a maximum daily dose of 150 mg. Bupropion is not recommended in patients with end‑stage renal disease.
• Switching to or from an MAOI: At least 14 days must elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with Wellbutrin. Conversely, at least 14 days should be allowed after stopping Wellbutrin before starting an MAOI antidepressant.
• Administration: Wellbutrin XL tablets should be swallowed whole with a glass of water. They should not be crushed, chewed, or divided, as this would release the entire drug at once, increasing the risk of side effects, including seizures. The tablets should be taken once daily in the morning to minimise the risk of insomnia. The insoluble shell of the extended‑release tablet may remain intact during gastrointestinal transit and may be visible in the stool; this is normal and does not mean the medication was not absorbed.
• Missed dose: If a dose is missed, skip the missed dose and take the next dose at the regular time the following morning. Do not double the dose or take a dose late in the day to make up for a missed one, as this increases the risk of insomnia and seizures.
• Discontinuation: Gradual dose tapering is recommended when discontinuing Wellbutrin to minimise the risk of withdrawal symptoms. For patients on 300 mg daily, decrease to 150 mg once daily before complete discontinuation.

Side Effects and Contraindications

• Most common side effects (incidence ≥ 5% and at least twice the placebo rate): Dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitations, excessive sweating, tinnitus, myalgia, anorexia, and urinary frequency. Weight loss (14‑28%) is more pronounced with bupropion than with SSRIs and may be beneficial in some patients; weight should be monitored, especially in underweight patients.
• Common side effects: Headache, constipation, tachycardia, and blurred vision. Insomnia (11‑40%) is the most commonly reported side effect and can be minimised by taking the medication in the morning and avoiding late‑afternoon or evening doses.
• Serious adverse reactions: Seizures (dose‑dependent; incidence ~0.1% at ≤300 mg/day, increasing to 0.4% at 400 mg/day and ~4% at 450–600 mg/day), hypertension (including treatment‑emergent hypertension in ~2% of patients in SAD trials), activation of mania or hypomania, psychosis and other neuropsychiatric reactions (delusions, hallucinations, paranoia, confusion), angle‑closure glaucoma, anaphylaxis and anaphylactoid reactions, Stevens‑Johnson syndrome, erythema multiforme, and serum sickness‑like reactions. Cases of hepatotoxicity have also been reported.
• Overdose: An overdose of bupropion is a medical emergency. Symptoms of acute overdose may include seizures, hallucinations, loss of consciousness, sinus tachycardia, conduction disturbances (including QRS prolongation), and cardiac arrest. Seizures are the most common serious adverse effect of overdose. Immediate hospitalisation is required, with continuous cardiac monitoring and supportive care. There is no specific antidote. Activated charcoal may be considered in patients presenting within 1 hour of ingestion, provided the airway is protected.
• Contraindications: Current seizure disorder or history of seizures. Current or prior diagnosis of bulimia nervosa or anorexia nervosa. Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs. Concomitant use with monoamine oxidase inhibitors (MAOIs) intended to treat psychiatric disorders, including linezolid and intravenous methylene blue. Known hypersensitivity to bupropion hydrochloride or any excipient in the formulation. Concomitant use with other bupropion‑containing products (risk of additive seizure risk).

Drug Interactions

• Monoamine oxidase inhibitors (MAOIs) — contraindicated: Concomitant use of bupropion with MAOIs, including linezolid and intravenous methylene blue, is contraindicated due to the risk of hypertensive reactions. A minimum 14‑day washout period is required between discontinuation of an MAOI and initiation of bupropion, and vice versa.
• Drugs metabolised by CYP2D6 — dose adjustment may be required: Bupropion is a strong inhibitor of CYP2D6 and may significantly increase plasma concentrations of drugs metabolised by this isoenzyme. These include many antidepressants (venlafaxine, duloxetine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (haloperidol, risperidone, aripiprazole), beta‑blockers (metoprolol, propranolol), atomoxetine, and Type 1C antiarrhythmics (propafenone, flecainide). The dose of vortioxetine should be reduced by 50% when co‑administered with bupropion. Bupropion may also reduce the efficacy of prodrugs requiring CYP2D6 activation, such as tamoxifen.
• Drugs that lower the seizure threshold: Concomitant use of bupropion with other medications that lower the seizure threshold (e.g., antipsychotics, tricyclic antidepressants, theophylline, systemic corticosteroids, and other bupropion‑containing products) increases the risk of seizures. This combination should be avoided when possible or used with extreme caution.
• CYP2B6 inhibitors: Ticlopidine and clopidogrel inhibit CYP2B6 and may increase bupropion plasma concentrations. A dose reduction of bupropion should be considered.
• CYP2B6 inducers: Carbamazepine, phenobarbital, phenytoin, ritonavir, lopinavir, and efavirenz induce CYP2B6 and may decrease bupropion plasma concentrations, potentially reducing therapeutic efficacy. A dose increase of bupropion may be considered, but the maximum recommended dose should not be exceeded.
• Dopaminergic drugs: Caution is advised when bupropion is co‑administered with levodopa or amantadine due to the potential for additive central nervous system toxicity, including agitation, confusion, and psychosis.
• Nicotine replacement therapy (NRT): The combination of bupropion and nicotine transdermal system (NTS) has been associated with a higher incidence of treatment‑emergent hypertension (6.1%) compared with bupropion alone (2.5%), NTS alone (1.6%), or placebo (3.1%). Blood pressure should be monitored in patients receiving this combination.
• Alcohol: Alcohol consumption should be avoided or limited to a minimum during treatment with bupropion. The combination may increase the risk of neuropsychiatric side effects and seizures.
• Drug‑laboratory test interactions: Bupropion may cause false‑positive urine test results for amphetamines. Patients should inform their healthcare provider and testing laboratory that they are taking bupropion if a urine drug screen is required.

Practical Advice

• Administration: Take Wellbutrin XL once daily in the morning with a glass of water. Swallow the tablet whole; do not crush, chew, or divide it. The medication may be taken with or without food. Taking it early in the day helps minimise the risk of insomnia, which is the most common side effect. If you see a tablet shell in your stool, this is normal and does not indicate that the medication was not absorbed.
• Monitoring: Regular follow‑up with your doctor is essential, particularly during the first few weeks of treatment and after dosage changes. Blood pressure should be assessed before initiating therapy and monitored periodically during treatment. Patients with pre‑existing hypertension, cardiac disease, or those receiving nicotine replacement therapy concurrently require closer blood pressure monitoring. Weight should be monitored periodically, as bupropion commonly causes weight loss. In patients with hepatic or renal impairment, liver function tests and renal function should be monitored. All patients should be observed for clinical worsening, emergence of suicidal thoughts or behaviour, and unusual changes in mood or behaviour.
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep out of the reach and sight of children. Bupropion overdose can be fatal, and the medication should be stored securely.
• Lifestyle: Wellbutrin is most effective when used as part of a comprehensive treatment plan that includes psychotherapy, lifestyle changes, and social support. Maintain a regular sleep schedule and practise good sleep hygiene, but avoid taking the medication late in the day. Limit or avoid alcohol entirely. If you are using bupropion as part of a smoking cessation programme, set a target quit date and engage in counselling and behavioural support for best results. Do not drive or operate heavy machinery until you know how the medication affects you. Rising slowly from a sitting or lying position may help minimise dizziness.
• Missed dose: If you miss a dose, skip the missed dose entirely and take your next dose at the usual time the following morning. Never double the dose or take a dose late in the day to compensate for a missed one.
• When to seek medical review: Contact your doctor immediately if you experience a seizure, signs of a serious allergic reaction (rash, hives, swelling of the face, lips, tongue, or throat, difficulty breathing), signs of an acute angle‑closure glaucoma attack (sudden eye pain, decreased vision, halos around lights, headache, nausea), hallucinations, paranoia, or severe agitation. Seek emergency medical attention for any suicidal thoughts or self‑harm urges. An overdose of bupropion is a life‑threatening emergency; call 911 or your local emergency number immediately if an overdose is suspected.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Selective serotonin reuptake inhibitors (SSRIs): Sertraline (Zoloft), escitalopram (Cipralex), fluoxetine (Prozac), paroxetine (Paxil), and citalopram (Celexa) are first‑line antidepressants for major depressive disorder. They act primarily on serotonin and are generally well tolerated, but they are more likely to cause sexual dysfunction and weight gain than bupropion.
• Serotonin‑norepinephrine reuptake inhibitors (SNRIs): Venlafaxine (Effexor XR), duloxetine (Cymbalta), and desvenlafaxine (Pristiq) are first‑line antidepressants that target both serotonin and norepinephrine. Duloxetine also has approved indications for neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. They are more likely to cause nausea and sexual dysfunction than bupropion.
• Mirtazapine (Remeron): An atypical antidepressant that enhances norepinephrine and serotonin release through alpha‑2 adrenergic receptor antagonism. It provides sedation and appetite stimulation, making it useful for patients with insomnia and poor appetite, but it commonly causes significant weight gain—the opposite profile of bupropion.
• Vortioxetine (Trintellix): A multimodal antidepressant that combines serotonin reuptake inhibition with modulation of multiple serotonin receptors. It has a favourable cognitive profile but is more likely to cause nausea than bupropion. When used with bupropion, the vortioxetine dose must be reduced by 50%.
• Agomelatine (Valdoxan): An atypical antidepressant that acts as a melatonin receptor agonist and 5‑HT_2C antagonist. It improves sleep without daytime sedation and does not cause sexual dysfunction or weight gain. It requires periodic liver function monitoring.
• Tricyclic antidepressants (TCAs): Amitriptyline (Elavil), nortriptyline (Aventyl), and imipramine (Tofranil) are older agents with established efficacy for depression and neuropathic pain. They carry a higher burden of anticholinergic side effects, sedation, and cardiotoxicity in overdose compared with bupropion.
• For smoking cessation (bupropion SR alternatives): Varenicline (Champix) is a first‑line pharmacotherapy for smoking cessation with superior efficacy to bupropion SR. Nicotine replacement therapy (patch, gum, lozenge, inhaler) is available without a prescription and can be used alone or in combination.
• Non‑pharmacological approaches: Cognitive behavioural therapy (CBT), interpersonal therapy (IPT), and behavioural activation are evidence‑based psychotherapies for depression. For seasonal affective disorder, light therapy (bright light exposure, typically 10,000 lux for 30 minutes each morning) is a first‑line treatment with a strong evidence base. Exercise, mindfulness‑based stress reduction, and good sleep hygiene are important complementary measures.

Clinical Efficacy

The efficacy of bupropion for the treatment of major depressive disorder has been established in numerous randomised, double‑blind, placebo‑controlled clinical trials. In short‑term studies of 6 to 8 weeks' duration, bupropion produced a significantly greater reduction in depression rating scale scores compared with placebo, with response rates of approximately 50‑60%. In the landmark STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial, bupropion sustained‑release was evaluated as both a switch strategy and an augmentation strategy in patients who had not responded to initial treatment with the SSRI citalopram. As monotherapy, bupropion SR produced remission rates of 25‑30% in patients who had failed citalopram. As an augmentation agent added to ongoing SSRI therapy, bupropion SR produced remission rates of approximately 30‑39%, comparable to those achieved with buspirone augmentation and superior to buspirone in anxious depression.

For the prevention of seasonal affective disorder, bupropion XL is the only antidepressant with a specific prophylactic indication. Three randomised, placebo‑controlled trials conducted over 3 years in patients with a history of recurrent winter depression demonstrated that bupropion XL significantly reduced the incidence of seasonal depressive relapse compared with placebo. In the pooled analysis, the overall rate of depression‑free survival at the end of treatment was 84% for bupropion XL compared with 72% for placebo, representing a 44% relative risk reduction.

For smoking cessation, bupropion SR has been shown in multiple randomised controlled trials to approximately double the odds of long‑term abstinence compared with placebo, with 12‑month continuous abstinence rates of approximately 18‑24% compared with 8‑12% for placebo. The combination of bupropion SR and nicotine replacement therapy has shown some additive benefit, although with a higher incidence of treatment‑emergent hypertension. Bupropion is recommended as a first‑line pharmacotherapy for smoking cessation by the Canadian Action Network for the Advancement, Dissemination and Adoption of Practice‑informed Tobacco Treatment (CAN‑ADAPTT).

A key advantage of bupropion over SSRIs and SNRIs is its favourable sexual side‑effect profile. In a 2024 meta‑analysis and numerous comparative studies, bupropion was consistently associated with a significantly lower incidence of treatment‑emergent sexual dysfunction compared with SSRIs and SNRIs, making it a preferred option for patients for whom sexual side effects are a concern. Bupropion is also weight‑neutral or associated with modest weight loss, in contrast to the weight gain commonly seen with SSRIs and SNRIs. The Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 clinical guidelines list bupropion as a first‑line pharmacological treatment for major depressive disorder in adults, particularly for patients with hypersomnia, fatigue, or concerns about sexual dysfunction or weight gain.

Important:

Wellbutrin (bupropion) is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It carries a boxed warning for an increased risk of suicidal thinking and behaviour in children, adolescents, and young adults under 24 years of age. All patients, regardless of age, should be closely monitored for clinical worsening, suicidality, or unusual changes in behaviour, particularly during the first few months of treatment and after dosage changes. This medication can lower the seizure threshold; the risk of seizure is dose‑related and is increased in patients with certain medical conditions (seizure disorder, eating disorders, head trauma, CNS tumour or infection), in those undergoing abrupt discontinuation of alcohol or sedatives, and with concomitant use of other medications that lower the seizure threshold. Do not exceed the maximum recommended dose of 300 mg per day for the XL formulation. Wellbutrin can increase blood pressure; blood pressure should be monitored before and during treatment. Alcohol should be avoided or strictly limited. Do not crush, chew, or divide the extended‑release tablets. Wellbutrin is contraindicated with MAOIs; a 14‑day washout period is required before starting bupropion after stopping an MAOI, and vice versa. If you experience a seizure, signs of a serious allergic reaction (rash, swelling of the face or throat, difficulty breathing), hallucinations, paranoia, severe agitation, or sudden eye pain with decreased vision, seek emergency medical attention immediately. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Wellbutrin - Shipping across Canada